The article discusses the results of the Age-Related Eye Disease Study 1 (AREDS1) and AREDS 2. It mentions that AREDS 1 revealed reduction in progression of age related macular degeneration (AMD) with antioxida
AREDS2 data was first published in 2013 and tested several variations of the original AREDS formula. The primary goal was to test if adding lutein and zeaxanthin or omega-3 fatty acids would make the original AREDS formula more effective. One formula also tested a significantly reduced zinc leve...